Literature DB >> 23086198

Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism.

Ryan T Bushey1, Douglas F Dluzen, Philip Lazarus.   

Abstract

UDP-glucuronosyltransferase A1 (UGT2A1) is expressed in the lung and exhibits activity against polycyclic aromatic hydrocarbons (PAHs), suggesting UGT2A1 involvement in the local metabolism of PAH tobacco carcinogens. The goal of the present study was to investigate the importance of two additional UGT2A enzymes, UGT2A2 and UGT2A3, in tobacco carcinogen metabolism. Real-time polymerase chain reaction suggested that wild-type UGT2A2 had the highest expression in the breast, followed by trachea > larynx > kidney. A novel splice variant of UGT2A2 lacking exon 3 (termed UGT2A2Δexon3) was investigated, with UGT2A2Δexon3 expression determined to be 25-50% that of wild-type UGT2A2 in all tissues examined. UGT2A3 was determined to be well expressed in the liver and colon, followed by pancreas > kidney > lung > tonsil > trachea > larynx. Cell homogenates prepared from human embryonic kidney (HEK)293 cells overexpressing wild-type UGT2A2 (termed UGT2A2_i1) exhibited glucuronidation activity, as observed by reverse-phase ultra-pressure liquid chromatography, against 1-hydroxy-(OH)-pyrene, 1-naphthol, and hydroxylated benzo(a)pyrene metabolites, whereas homogenates prepared from HEK293 cells overexpressing UGT2A3 only showed activity against simple PAHs like 1-OH-pyrene and 1-naphthol. Activity assays showed the UGT2A2Δexon3 protein (termed UGT2A2_i2) exhibited no detectable glucuronidation activity against all substrates examined; however, coexpression studies suggested that UGT2A2_i2 negatively modulates UGT2A2_i1 activity. Both UGT2A2 and UGT2A3 exhibited no detectable activity against complex PAH proximate carcinogens, tobacco-specific nitrosamines, or heterocyclic amines. These data suggest that, although UGT2A1 is the only UGT2A enzyme active against PAH proximate carcinogens (including PAH diols), both UGTs 2A1 and 2A2 play an important role in the local detoxification of procarcinogenic monohydroxylated PAH metabolites.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086198      PMCID: PMC3533432          DOI: 10.1124/dmd.112.049171

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  31 in total

1.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

2.  Expression of the tumor suppressor gene Maspin in human pancreatic cancers.

Authors:  N Maass; T Hojo; M Ueding; J Lüttges; G Klöppel; W Jonat; K Nagasaki
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

Review 3.  UDP-glucuronosyltransferases.

Authors:  B Burchell; M W Coughtrie
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

4.  Improved tools for biological sequence comparison.

Authors:  W R Pearson; D J Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

5.  Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes.

Authors:  Jia-Long Fang; Frederick A Beland; Daniel R Doerge; Doris Wiener; Chantal Guillemette; M Matilde Marques; Philip Lazarus
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

6.  O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9.

Authors:  Q Ren; S E Murphy; Z Zheng; P Lazarus
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

7.  Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines.

Authors:  Gang Chen; Ryan W Dellinger; Carla J Gallagher; Dongxiao Sun; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2008-03       Impact factor: 2.089

8.  Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10.

Authors:  Ryan W Dellinger; Gang Chen; Andrea S Blevins-Primeau; Jacek Krzeminski; Shantu Amin; Philip Lazarus
Journal:  Carcinogenesis       Date:  2007-07-17       Impact factor: 4.944

9.  Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7.

Authors:  Peter Mackenzie; Joanna M Little; Anna Radominska-Pandya
Journal:  Biochem Pharmacol       Date:  2003-02-01       Impact factor: 5.858

10.  Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.

Authors:  Verawan Uchaipichat; Peter I Mackenzie; Xiao-Hui Guo; Dione Gardner-Stephen; Aleksandra Galetin; J Brian Houston; John O Miners
Journal:  Drug Metab Dispos       Date:  2004-04       Impact factor: 3.922

View more
  12 in total

1.  Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues.

Authors:  A Tourancheau; M Rouleau; S Guauque-Olarte; L Villeneuve; I Gilbert; A Droit; C Guillemette
Journal:  Pharmacogenomics J       Date:  2017-04-25       Impact factor: 3.550

2.  Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing.

Authors:  A Tourancheau; G Margaillan; M Rouleau; I Gilbert; L Villeneuve; E Lévesque; A Droit; C Guillemette
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

Review 3.  Logic of the Temporal Compartmentalization of the Hepatic Metabolic Cycle.

Authors:  Bokai Zhu
Journal:  Physiology (Bethesda)       Date:  2022-06-06

4.  RNA-sequencing quantification of hepatic ontogeny and tissue distribution of mRNAs of phase II enzymes in mice.

Authors:  Hong Lu; Sumedha Gunewardena; Julia Y Cui; Byunggil Yoo; Xiao-bo Zhong; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2013-02-04       Impact factor: 3.922

Review 5.  PharmGKB summary: very important pharmacogene information for UGT1A1.

Authors:  Julia M Barbarino; Cyrine E Haidar; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2014-03       Impact factor: 2.089

6.  The Human UDP-glucuronosyltransferase UGT2A1 and UGT2A2 enzymes are highly active in bile acid glucuronidation.

Authors:  Martin Perreault; Louis Gauthier-Landry; Jocelyn Trottier; Mélanie Verreault; Patrick Caron; Moshe Finel; Olivier Barbier
Journal:  Drug Metab Dispos       Date:  2013-06-11       Impact factor: 3.922

7.  Carbonyl reduction of NNK by recombinant human lung enzymes: identification of HSD17β12 as the reductase important in (R)-NNAL formation in human lung.

Authors:  Joseph H Ashmore; Shaman Luo; Christy J W Watson; Philip Lazarus
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

8.  Regulation of UGT2A1 by miR-196a-5p and miR-196b-5p.

Authors:  Aimee K Sutliff; Christy J W Watson; Gang Chen; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2019-03-08       Impact factor: 4.030

9.  UDP-glucuronosyltransferase 1A compromises intracellular accumulation and anti-cancer effect of tanshinone IIA in human colon cancer cells.

Authors:  Miao Liu; Qiong Wang; Fang Liu; Xuefang Cheng; Xiaolan Wu; Hong Wang; Mengqiu Wu; Ying Ma; Guangji Wang; Haiping Hao
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Reduction of p53 by knockdown of the UGT1 locus in colon epithelial cells causes an increase in tumorigenesis.

Authors:  Miao Liu; Shujuan Chen; Mei-Fei Yueh; Guangji Wang; Haiping Hao; Robert H Tukey
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.